Sign In
Buy DNLI
$19.66
+0.310 (+1.60%)
At Close: Jun 03, 2026
Denali Therapeutics (NASDAQ:DNLI) Stock Rating Lowered by Zacks Investment Research
01:22am, Wednesday, 24'th Jun 2020
Denali Therapeutics (NASDAQ:DNLI) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Monday, Zacks.com reports. According to Za
Dow Sheds Nearly 7% as Pullback Finally Arrives
12:00am, Friday, 12'th Jun 2020
Stocks Analysis by Zacks Investment Research covering: SPDR S&P 500, Union Pacific Corporation, KeyCorp, CarMax Inc. Read Zacks Investment Research's latest article on Investing.com
Sanofi and Denali Halt Clinical Trials of Alzheimer Drug
06:03pm, Wednesday, 10'th Jun 2020
The companies are shifting their joint efforts from DNL747 to DNL788, which has stronger preclinical data.
Denali Drops 7% In After-Market On Halt Of DNL747 Drug Study
06:51am, Wednesday, 10'th Jun 2020
Denali Therapeutics Inc. (DNLI) announced that it is pausing clinical studies of DNL747, its neurological drug candidate for the treatment of Alzheimer’s disease and ALS, sending shares down some 7%
Denali Therapeutics Provides Broad Update on Its RIPK1 Program Partnered With Sanofi
08:30pm, Tuesday, 09'th Jun 2020
Denali and Sanofi pause DNL747(a) clinical activities based on the totality of DNL747 data and a superior profile of backup compound DNL788(b)Denali and Sanofi intend to.
NGM Bio Expands Board of Directors with Appointment of Carole Ho, M.D.
12:00pm, Monday, 08'th Jun 2020
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today
New research offers hope for a way through the blood-brain barrier
11:37am, Monday, 01'st Jun 2020
A duo of preclinical studies recently demonstrated a new way to ferry medicines past the blood-brain barrier. And other research is on the way.
Venture Funding of Drug Startups Down, But Not Out
03:21pm, Thursday, 28'th May 2020
Fourteen biotechs have gone public in 2020, just three fewer than for the same period last year Continue reading...
Flagship Pioneering, a unique life sciences innovation enterprise, today announced that it has further strengthened its executive leadership team with the appointment of Fabrice Chouraqui to the newly
Denali’s “Transport Vehicle” technology enables broad distribution and improved exposure levels of therapeutic proteins throughout the brainClinical proof of concept data with.
What Makes Denali Therapeutics Inc. (DNLI) a New Buy Stock
04:00pm, Thursday, 21'st May 2020
Denali Therapeutics Inc. (DNLI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Analyst Estimates: Here's What Brokers Think Of Denali Therapeutics Inc. (NASDAQ:DNLI) After Its First-Quarter Report
01:18pm, Sunday, 10'th May 2020
Investors in Denali Therapeutics Inc. (NASDAQ:DNLI) had a good week, as its shares rose 9.6% to close at US$23.89...
Denali Therapeutics Inc (DNLI) Reports Q1 Loss, Lags Revenue Estimates
12:20am, Friday, 08'th May 2020
Denali Therapeutics Inc (DNLI) delivered earnings and revenue surprises of 3.51% and -39.19%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock
Denali Therapeutics Reports First Quarter 2020 Financial Results and Provides COVID-19 Response Update
08:30pm, Thursday, 07'th May 2020
SOUTH SAN FRANCISCO, May 07, 2020 -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross.
Analysts Estimate Denali Therapeutics Inc. (DNLI) to Report a Decline in Earnings: What to Look Out for
04:30pm, Wednesday, 06'th May 2020
Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
